Preclinical studies reported several dual PI3K/mTOR inhibitors that effectively inhibited NPC cell proliferation, including BEZ235 [18], PF-04691502 [19], GSK2126458, and PKI-587 [20]. Here, PIK3CA is linked to nasopharyngeal carcinoma.